前收市價 | 0.0400 |
開市 | 0.0500 |
買盤 | 0.0000 |
賣出價 | 0.0500 |
拍板 | 2.00 |
到期日 | 2024-05-17 |
今日波幅 | 0.0400 - 0.0500 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 3.74k |
Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result. And poor results can happen to anybody, big or small. Indeed, the prospect of being on the wrong end of a giant killing adds significant risk to market participants. So, as a calculated approach, since you’re going to be tak